Evaluation of liver fibrosis in patients with thalassemia: The important role of hyaluronic acid

Blood Cells, Molecules, and Diseases

Volumn 45, Issue 3, 2010, Pages 215-218

  Papastamataki, Maria ^a   Delaporta, Polyxeni ^b   Premetis, Evangelos ^a   Kattamis, Antonios ^b   Ladis, Vassilios ^b   Papassotiriou, Ioannis ^a  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hepascore; Hyaluronic acid; Liver fibrosis; Thalassemia

Indexed keywords

FERRITIN; HYALURONIC ACID; IRON; VIRUS RNA;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL CHEMISTRY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; SCREENING TEST; THALASSEMIA MAJOR; TURBIDIMETRY;

ADULT; EVALUATION STUDIES AS TOPIC; FEMALE; FERRITINS; HEPACIVIRUS; HEPATITIS C; HUMANS; HYALURONIC ACID; IRON; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; SIDEROSIS; THALASSEMIA;

HEPATITIS C VIRUS;

EID: 77956875235     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2010.06.002     Document Type: Article

References (27)

1. Prati D., Maggioni M., Milani S., Cerino M., Cianciulli P., Coggi G., Forni G.L., Magnano C., Meo A., Gramignoli R., Rebulla P., Fiorelli G., Cappellini M.D. Clinical and histological characterization of liver disease in patients with transfusion-dependent β-thalassemia. A multicenter study of 117 cases. Haematologica 2004, 89:1179-1186.
2. Sebastiani G., Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol. 2006, 12:3682-3694.
3. Angelucci E., Brittenham G.M., McLaren C.E., Ripalti M., Baronciani D., Giardini C., Galimberti M., Polchi P., Lucarelli G. Hepatic iron concentration and total body iron stores in thalassemia major. N. Engl. J. Med. 2000, 343:327-331.
4. Gilmore I.T., Burroughs A., Murray-Lyon I.M., Williams R., Jenkins D., Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995, 36:437-441.
5. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. N. Engl. J. Med. 2001, 344:495-500.
6. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., Kench J., Farrell G., McCaughan G.W., Jeffrey G.P. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 2005, 51:1867-1873.
7. Guechot J., Lasnier E., Sturm N., Paris A., Zarski J.-P. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin. Chim. Acta 2009, 411:86-91. the ANRS HC EP 23 Fibrostar study group.
8. Halfon P., Bourliere M., Penaranda G., Deydier R., Renou C., Botta-Fridlund D., Tran A., Portal I., Allemand I., Rosenthal-Allieri A., Ouzan D. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp. Hepatol. 2005, 4:6.
9. Other Leroy V. Non-ivasive markers of liver fibrosis. Gastroentérol. Clin. Biol. 2008, 32:52-57.
10. Lee H.H., Seo Y.S., Um S.H., Won N.H., Yoo H., Jung E.S., Kwon Y.D., Park S., Keum B., Kim Y.S., Yim H.J., Jeen Y.T., Chun H.J., Kim C.D., Ryu H.S. Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease. J. Korean Med. Sci. 2010, 25:67-74.
11. Shaheen A.A.M., Myers R.P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46:912-921.
12. Boursier J., Bacq Y., Halfon P., Leroy V., De Ledinghen V., De Muret A., Bourliere M., Sturm N., Foucher J., Oberti F., Rousselet M.C., Cales P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur. J. Gastroenterol. Hepatol. 2009, 21:28-38.
13. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J., Kench J., Farrell G., McCaughan G.W., Jeffrey G.P. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 2005, 51:1867-1873.
14. Becker L., Salameh W., Sferruzza A., Zhang K., Chen R., Malik R., Reitz R., Nasser I., Afdhal N.H. Validation of Hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin. Gastroenterol. Hepatol. 2009, 7:696-701.
15. Di Marco V., Bronte F., Cabibi D., Calvaruso V., Alaimo G., Borsellino Z., Gagliardotto F., Almasio P.L., Capra M., Craxi A. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. Br. J. Haematol. 2010, 148:476-479.
16. Lindqvist U., Laurent T.C. Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand. J. Clin. Lab. Invest. 1992, 52:613-621.
17. Gibson P.R., Fraser J.R., Brown T.J., Finch C.F., Jones P.A., Colman J.C., Dudley F.J. Hemodynamic and liver function predictors of serum hyaluronan in alcoholic liver disease. Hepatology 1992, 15:1054-1059.
18. Poupon R.E., Balkau B., Guechot J., Heintzmann F. Predictive factors in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: role of serum markers of connective tissue. Hepatology 1994, 19:635-640.
19. Azer S.A., Murray M., Farrell G.C., Stacey N.H. Selectivity and sensitivity of changes in serum bile acids during induction of cirrhosis in rats. Hepatology 1993, 18:1224-1231.
20. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer E., Bruguera M., Sanchez-Tapias J.M., Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
21. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
22. Myers R.P., Tainturier M.H., Ratziu V., Piton A., Thibault V., Imbert-Bismut F., Messous D., Charlotte F., Di Martino V., Benhamou Y., Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol. 2003, 39:222-230.
23. Vrochides D., Papanikolaou V., Pertoft H., Antoniades A.A., Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. Hepatology 1996, 23:1650-1655.
24. Kawser C.A., Iredale J.P., Winwood P.J., Arthur M.J. Rat hepatic stellate cell expression of α2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin. Sci. (Lond.) 1998, 95:179-186.
25. Wood J.C., Enriquez C., Ghugre N., Tyzka J.M., Carson S., Nelson M.D., Coates T.D. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood 2005, 106:1460-1465.
26. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997, 349:825-832.
27. Ryder S.D., Irving W.L., Jones D.A., Neal K.R., Underwood J.C. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004, 53:451-455.